Gene · 5916
RARG: retinoic acid receptor gamma
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RARG: retinoic acid receptor gamma. Genes, record 5916. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5916
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P13631 | Retinoic acid receptor gamma | 454 | 11 | Ensembl, GeneID, HGNC |
Source UniProt
Patents46
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61530 | P13631 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61531 | P13631 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 12246 | P13631 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 1980 | P13631 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 13305 | P13631 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 6150 | P13631 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15550 | P13631 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 1980 | P13631 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 13305 | P13631 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 12246 | P13631 | Espacenet |
1 to 10 of 46
See all 46 patentsDrugs11
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACITRETIN | CHEMBL1131 | Retinoid receptor agonist | AGONIST | ChEMBL |
| ADAPALENE | CHEMBL1265 | Retinoic acid receptor agonist | AGONIST | ChEMBL |
| ALITRETINOIN | CHEMBL705 | Retinoid receptor agonist | AGONIST | ChEMBL |
| ETRETINATE | CHEMBL464 | Retinoid receptor agonist | AGONIST | ChEMBL |
| IRX4310 | CHEMBL3545173 | Retinoic acid receptor antagonist | ANTAGONIST | ChEMBL |
| ISOTRETINOIN | CHEMBL547 | Retinoic acid receptor agonist | AGONIST | ChEMBL |
| MOFAROTENE | CHEMBL146506 | Retinoid receptor modulator | MODULATOR | ChEMBL |
| PALOVAROTENE | CHEMBL2105648 | Retinoic acid receptor gamma agonist | AGONIST | ChEMBL |
| TAZAROTENE | CHEMBL1657 | Retinoic acid receptor agonist | AGONIST | ChEMBL |
| TRETINOIN | CHEMBL38 | Retinoic acid receptor agonist | AGONIST | ChEMBL |
1 to 10 of 11
See all 11 drugsTrials502
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07597395 | TRETINOIN | PHASE3 | ClinicalTrials.gov | |
| NCT07586826 | TRETINOIN | PHASE2 | ClinicalTrials.gov | |
| NCT07586813 | TRETINOIN | PHASE2 | ClinicalTrials.gov | |
| NCT07524946 | ADAPALENE | PHASE4 | ClinicalTrials.gov | |
| NCT07504458 | TRETINOIN | PHASE3 | ClinicalTrials.gov | |
| NCT07503730 | TRETINOIN | PHASE3 | ClinicalTrials.gov | |
| NCT07485777 | TRETINOIN | ClinicalTrials.gov | ||
| NCT07481370 | ISOTRETINOIN | PHASE2 | ClinicalTrials.gov | |
| NCT07473895 | ADAPALENE | PHASE2 | ClinicalTrials.gov | |
| NCT07469228 | TRETINOIN | PHASE1 | ClinicalTrials.gov |
1 to 10 of 502
See all 502 trialsNIH grants1,608
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RARG papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 8 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 4 | 2025 |
| T32CA009512 | Clinical Scholars Biomedical Research Training Program | 4 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 3 | 2025 |
| P30AR069619 | Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application) | 3 | 2025 |
1 to 10 of 1,608Source NIH's project files
See all 1,608 nih grantsPapers2,651
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Rare Cancer-Associated Mutations May Affect the AF1 Phosphoregulatory Domain of RARγ. | Genes (Basel) | 2026 | 42793013 | PubTator, text mining | PubMed |
| Dual HBV cccDNA-linked HiBiT reporter hepatocyte models for screening of candidate cccDNA modulators. | Virulence | 2026 | 42697841 | PubTator, text mining | PubMed |
| Stable simulations do not guarantee functional engagement: a case study of off-target prediction for Seladelpar and Zanamivir. | J Comput Aided Mol Des | 2026 | 42690469 | PubTator, text mining | PubMed |
| Genomic diversification between aposematic and cryptic phenotypes of Oophaga granulifera (Anura: Dendrobatidae). | Sci Rep | 2026 | 42661044 | PubTator, text mining | PubMed |
| Barrier Function and Biophysical Effects of 0.104% and 0.247% Retinol Creams in Mature Facial Skin: A Prospective Study. | Int J Mol Sci | 2026 | 42653210 | PubTator, text mining | PubMed |
| Trifarotene for Facial and Truncal Acne Vulgaris: A Narrative Review of Clinical Trial Evidence. | Cureus | 2026 | 42615018 | PubTator, text mining | PubMed |
| Successful Trifarotene Treatment of a Typical Kyrle's Disease With Overview of Topical Therapies. | Skin Res Technol | 2026 | 42480558 | PubTator, text mining | PubMed |
| Structural and Thermodynamic Discrimination between Agonists and Antagonists of Retinoic Acid Receptor γ and the Vitamin D Receptor. | J Chem Inf Model | 2026 | 42378554 | PubTator, text mining | PubMed |
| Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression. | BMC Cancer | 2026 | 42365243 | PubTator, text mining | PubMed |
| Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies. | Cancers (Basel) | 2026 | 42279262 | PubTator, text mining | PubMed |
1 to 10 of 2,651
See all 2,651 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5916
GET https://conductscience.org/api/genes/v1/5916/patents?page=2